Swiss National Bank
CBAY

Swiss National Bank’s Cymabay Therapeutics CBAY Stock Holding History

Swiss National Bank’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-155,400
Closed -$3.67M – 2542
2023
Q4 		$3.67M Sell
155,400
-26,100
-14% -$465K ﹤0.01% 1477
2023
Q3 		$2.71M Buy
181,500
+22,600
+14% +$300K ﹤0.01% 1654
2023
Q2 		$1.74M Sell
158,900
-23,800
-13% -$222K ﹤0.01% 1980
2023
Q1 		$1.59M Buy
+182,700
New +$1.46M ﹤0.01% 1979
2021
Q2 		– Sell
-109,000
Closed -$495K – 2655
2021
Q1 		$495K Hold
109,000
– – ﹤0.01% 2457
2020
Q4 		$626K Buy
+109,000
New +$825K ﹤0.01% 2430
2020
Q2 		– Sell
-118,400
Closed -$175K – 2528
2020
Q1 		$175K Hold
118,400
– – ﹤0.01% 2424
2019
Q4 		$232K Buy
118,400
+2,500
+2% +$9.39K ﹤0.01% 2501
2019
Q3 		$593K Buy
115,900
+3,000
+3% +$18.2K ﹤0.01% 2296
2019
Q2 		$808K Buy
112,900
+2,300
+2% +$26K ﹤0.01% 2231
2019
Q1 		$1.47M Buy
110,600
+11,400
+11% +$121K ﹤0.01% 1856
2018
Q4 		$781K Buy
99,200
+2,500
+3% +$23.8K ﹤0.01% 2137
2018
Q3 		$1.07M Hold
96,700
– – ﹤0.01% 2112
2018
Q2 		$1.3M Buy
+96,700
New +$1.21M ﹤0.01% 2002

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Swiss National Bank's CBAY Position: Q1 2024 in Review

Swiss National Bank sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 155,400 shares — an estimated $3.67M sold.

Swiss National Bank first reported a position in CBAY in Q2 2018 and held it in 14 quarters. The position peaked at $3.67M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • Swiss National Bank reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Swiss National Bank sold 155,400 Cymabay Therapeutics shares in Q1 2024, an estimated $3.67M.
  • Swiss National Bank first reported a position in Cymabay Therapeutics in Q2 2018 and held it in 14 quarters.
  • Swiss National Bank's Cymabay Therapeutics position peaked at $3.67M in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Swiss National Bank's 13F filing for Q1 2024, filed 7 May 2024.